Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO
In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech AlzeCure Pharma enters a collaboration and out-licensing agreement with Eli Lilly for its Alzheimer's candidate, and FDA approves an every-eight-week maintenance dosing regimen for Eli Lilly's Ebglyss.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg
Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO
Pharmaceutical Executive Daily: China's Latest Policy Guidance
The Ron Lanton Report: From Innovation to Infrastructure
Get summaries like this every morning.
Free AI-powered recaps of Pharmaceutical Executive and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.